Rituximab (Anti-Cd20)-modified AZD-2014-encapsulated Nanoparticles Killing of B Lymphoma Cells

Xiaolong Tang,Chunmei Xie,Zhenyou Jiang,Amin Li,Shiyu Cai,Changhao Hou,Jian Wang,Yong Liang,Dong Ma
DOI: https://doi.org/10.1080/21691401.2018.1478844
2018-01-01
Artificial Cells Nanomedicine and Biotechnology
Abstract:The mTOR signal pathway is often highly activated in B-cell non-Hodgkin's lymphoma (NHL) and promotes cancer progression and chemo-resistance. Therefore, the pathways of mTOR are an important target for drug development in this disease. In the current study, we developed a rituximab (anti-CD20)-modified mTOR inhibitor, AZD-2014, loaded into nanoparticles (Ab-NPs-AZD-2014) for trial of its anti-NHL effect. In a cultured NHL cell line, Ab-NPs-AZD-2014 inhibited cancer cell growth, induced cell apoptosis, and blocked activation of mTORC1 and mTORC2 in Raji cells. These results indicate that antibody modification and nanomaterial loading of AZD-2014 with anti-CD20 significantly improved efficacy of AZD-2014 against NHL cells. This approach may ultimately deserve testing in therapy against NHL.
What problem does this paper attempt to address?